Liu Sh
2015
Citations
0
Influential Citations
0
Citations
Journal
Progress in Pharmaceutical Sciences
Abstract
On Jan 15, 2015, dasabuvir was approved by European Medicines Agency as monotherapy for the treatment of HCV. The drug was also approved by FDA on Dec 19, 2014 as combined therapy(dasabuvir/ombitasvir/paritaprevir/ritonavir) for the treatment of HCV genotype 1. Dasabuvir is a NS5 B RNA-dependent RNA polymerase inhibitor, which exerts anti-viral activity by interfering with HCV replication. The chemical synthesis, preclinical pharmacology, clinical trials and patent protection of dasabuvir were summarized in this article, so as to provide references for the RD of new anti-HCV drugs.